ClinicalTrials.gg
TerminatedNCT03037580Updated Nov 10, 2020Results posted

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

A Phase 3 interventional study of Oral treprostinil and Placebo in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction, sponsored by United Therapeutics. Terminated at 82 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-11-10.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated by sponsor

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
11th of 37
84 · median 32
Started
2017
with 3 others
Phase 3
15 of 38
1 open now
Registered
25th of 38
by date
Lead sponsor
25 of 38
United Therapeutics

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 11th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 15 in phase 3, and was the 25th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

This was a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Once randomized, subjects took the initial dose of study drug at the study site on the day of randomization. Subjects returned to the study site for visits scheduled at Weeks 6, 12, 18, and 24. The duration of study participation was approximately 28 weeks from Screening until study completion (includes a 30-day Screening Phase and 24-week Treatment Phase).

The study was discontinued by the Sponsor on 14 October 2019 due to slow enrollment. As only a small portion of the anticipated total subjects had been enrolled, with many terminating early due to the study termination, there was a limited ability to explore the effect of oral treprostinil in this indication in this study.

Read the detailed description

Study TDE-HF-301 was a multicenter, randomized, double-blind, placebo-controlled study designed to investigate the effect of oral treprostinil compared with placebo on exercise capacity in subjects with WHO Group 2 PH associated with HFpEF.

Once randomized, subjects were dispensed study drug and took an initial dose (0.125 mg) at the study site on the day of randomization. Dosing of study drug continued at 0.125 mg 3 times daily (TID; every 6 to 8 hours) with food. Dose increases could occur in 0.125-mg increments every 72 hours at the discretion of the Investigator up to a maximum allowable dose of 6 mg TID. Subjects received oral treprostinil as 0.125, 0.25, 1.0, or 2.5 mg sustained-release osmotic tablets (maximum dose 6 mg TID) or matching placebo. Doses of study drug were to be increased in the absence of dose-limiting drug-related adverse events (AEs) to ensure that each subject received the optimal dose throughout the study. Subjects returned for visits at Weeks 6, 12, 18, and 24. Subjects who terminated study drug early were asked to complete all remaining study visits. The study had an adaptive design where the maximum allowable dose was 2 mg until the Data Monitoring Committee had confirmed a satisfactory safety profile. After this confirmation, the maximum allowable dose was increased to 4 mg TID. This occurred after 45 subjects had been enrolled. A subsequent Data Monitoring Committee meeting, which occurred after 75 subjects had been enrolled, increased the maximum allowable dose to 6 mg TID.

Efficacy assessments consisted of 6-Minute Walk Distance (6MWD), blood collection for N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, clinical worsening, WHO Functional Class (FC), Borg dyspnea score, glycated hemoglobin (HbA1c), and Kansas City Cardiomyopathy Questionnaire (KCCQ).

Safety assessments consisted of AEs, physical examinations, vital signs, 12-lead electrocardiograms (ECGs), echocardiograms (ECHOs), heart failure signs and symptoms, pregnancy testing, clinical laboratory tests, hospitalizations due to cardiopulmonary indication, and worsening heart failure as demonstrated by outpatient administration of intravenous (IV) diuretics. Subjects could have optionally provided samples for the evaluation of biomarkers and pharmacogenomics.

Subjects that completed the 24-week treatment period on study drug were permitted to enter the open-label extension study (Study TDE-HF-302).

The study was discontinued by the Sponsor on 14 October 2019 due to slow enrollment. As only a small portion of the anticipated total subjects had been enrolled, with many terminating early due to the study termination, there was a limited ability to explore the effect of oral treprostinil in this indication in this study.

03

Conditions studied

  • Pulmonary Hypertension
  • Heart Failure With Preserved Ejection Fraction

Keywords

  • Pulmonary Hypertension
  • 6-Minute Walk Test
  • HFpEF
  • Oral Treprostinil
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily gave to participate in the study.
  2. The subject was 18 to 85 years of age (inclusive) at Screening (ie, date of providing written informed consent).
  3. A subject could qualify if they had undergone a right heart catheterization (RHC) within 180 days of Baseline.
  4. The subject had a diagnosis of heart failure with a (LVEF) ≥45% by ECHO completed during Screening (prior to randomization).
  5. The subject's baseline 6MWD was at least 150 meters.
  6. The subject had pulmonary function tests conducted within 6 months of Screening or during the Screening Phase.
  7. Subjects on a chronic medication for heart failure were on a stable dose for ≥30 days prior to randomization.
  8. In the opinion of the Investigator, the subject was able to communicate effectively with study personnel, and was considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.
  9. Women of , including any female who had experienced menarche and who had not undergone successful surgical sterilization or was not , must have practiced true abstinence from intercourse when it was in line with their preferred and usual lifestyle, or have used 2 different forms of highly effective for the duration of the study, and for at least 30 days after discontinuing study drug. Male subjects with a partner of childbearing potential must have used a condom during the length of the study, and for at least 48 hours after discontinuing study drug.
  10. Subjects on chronic medications (eg, inhaled , long-acting beta2 adrenergic agonist, long acting muscarinic antagonists, combination inhaled drugs, anti-inflammatory drugs, oral/parenteral corticosteroids, or biologic agents) for any underlying respiratory condition were on a stable dose for ≥30 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. The subject was pregnant or lactating.
  2. In the opinion of the Principal Investigator, the subject had a primary diagnosis of PH other than WHO Group 2 PH.
  3. The subject had shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation of therapy or inability to effectively titrate that therapy.
  4. The subject had received any approved pulmonary arterial hypertension (PAH) therapies within 30 days of randomization. Chronic use of an approved phosphodiesterase type 5 inhibitor (PDE5-I) was allowed as long as the subject has been on a stable dose for at least 90 days prior to randomization and had a RHC confirming the parameters necessary for inclusion in the study after being on a stable PDE5-I dose for at least 30 days.
  5. The subject had been hospitalized for a cardiopulmonary indication within 30 days of randomization.
  6. The subject had a myocardial infarction within 90 days of randomization.
  7. The subject had cardiac resynchronization therapy within 90 days of randomization or anticipated resynchronization therapy during the study treatment period.
  8. The subject had liver function tests greater than 3 times the at Screening, liver disease/dysfunction, known Class C hepatic disease, or noncirrhotic portal hypertension.
  9. The subject had uncontrolled systemic hypertension, systolic blood pressure \<100 mmHg, or a resting heart rate >100 beats per minute at Baseline.
  10. The subject had known genetic hypertrophic cardiomyopathy, sarcoidosis, or cardiac amyloidosis.
  11. The subject had a known history of any less than 40% by ECHO within 3 years of randomization. Note: a transient decline in LVEF below 40% that occurred and recovered more than 6 months before the start of Screening and was associated with an acute intercurrent condition (eg, atrial fibrillation) was allowed.
  12. The subject had hemodynamically significant valvular heart disease as determined by the Investigator, including: greater than mild aortic and/or mitral stenosis or severe mitral and/or aortic regurgitation (>Grade 3)
  13. The subject had a >45 kg/m\^2.
  14. The subject had any musculoskeletal disorder, or had any other condition that limited ambulation.
  15. The subject had end-stage renal disease requiring/receiving dialysis.
  16. The subject participated in an drug or device study within 30 days prior to the first dose of study drug.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Oral treprostinil

    Sustained-release oral tablets for TID administration

    Drug: Oral treprostinil

  • Placebo comparator
    Placebo

    Placebo (sugar pill) for TID oral administration

    Drug: Placebo

Interventions

  • Sustained-release oral tablets for TID administration

    Also known as: Treprostinil diethanolamine, treprostinil diolamine

  • DrugPlacebo

    Placebo (sugar pill) for TID oral administration

    Also known as: Matching placebo (sugar pill)

06

What researchers measure

Primary outcomes

  1. Change in 6MWD From Baseline to Week 24

    The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change in NT-proBNP Levels From Baseline to Week 24

    The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function.

    Time frame: Baseline to Week 24

  2. Number of Subjects With First Clinical Worsening Event From Baseline to Week 24

    Clinical worsening was defined as the occurrence of any 1 of the following clinical worsening events: hospitalization due to a cardiopulmonary indication (a non-elective hospitalization lasting at least 24 hours in duration caused by clinical conditions directly related to PH and/or heart failure), outpatient administration of IV diuretics, death (all causes), decrease in 6MWD \>15% from Baseline (or the subject was too ill to walk, and the cause was directly related to the disease under study) at 2 consecutive visits on different days (except Week 24).

    Time frame: Baseline to Week 24

  3. Change in WHO FC From Baseline to Week 24

    The WHO functional classification ranges from I (subject's disease does not affect daily activities) to IV (subject's disease causes severe impairment).

    Time frame: Baseline to Week 24

07

Results

Posted Oct 22, 2020

Participant flow

Participant flow — Overall Study
MilestoneOral TreprostinilPlacebo
Started4143
Completed2527
Not completed1616
Withdrew: Withdrawal by subject30
Withdrew: Adverse event10
Withdrew: Study terminated by sponsor1215
Withdrew: Death01

Outcome measures

PrimaryChange in 6MWD From Baseline to Week 24

The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living.

Time frame:
Baseline to Week 24
Reported as:
Median · meters
Change in 6MWD From Baseline to Week 24
metersOral TreprostinilPlacebo
Change in 6MWD From Baseline to Week 2421.0 (-195 to 62)23.3 (-140 to 104)
SecondaryChange in NT-proBNP Levels From Baseline to Week 24

The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function.

Time frame:
Baseline to Week 24
Reported as:
Median · pmol/L
Change in NT-proBNP Levels From Baseline to Week 24
pmol/LOral TreprostinilPlacebo
Change in NT-proBNP Levels From Baseline to Week 249.5 (-133 to 499)11.5 (-231 to 172)
SecondaryNumber of Subjects With First Clinical Worsening Event From Baseline to Week 24

Clinical worsening was defined as the occurrence of any 1 of the following clinical worsening events: hospitalization due to a cardiopulmonary indication (a non-elective hospitalization lasting at least 24 hours in duration caused by clinical conditions directly related to PH and/or heart failure), outpatient administration of IV diuretics, death (all causes), decrease in 6MWD \>15% from Baseline (or the subject was too ill to walk, and the cause was directly related to the disease under study) at 2 consecutive visits on different days (except Week 24).

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Number of Subjects With First Clinical Worsening Event From Baseline to Week 24
ParticipantsOral TreprostinilPlacebo
First Clinical Worsening Event65
No clinical worsening event3538
SecondaryChange in WHO FC From Baseline to Week 24

The WHO functional classification ranges from I (subject's disease does not affect daily activities) to IV (subject's disease causes severe impairment).

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Change in WHO FC From Baseline to Week 24
ParticipantsOral TreprostinilPlacebo
Baseline — WHO FC I11
Baseline — WHO FC II1917
Baseline — WHO FC III2124
Baseline — WHO FC IV01
Baseline — Not analyzed00
Week 24 — WHO FC I41
Week 24 — WHO FC II1016
Week 24 — WHO FC III1511
Week 24 — WHO FC IV00
Week 24 — Not analyzed1215

Adverse events

Collected over The Treatment Phase was 24 weeks for each subject. The study was discontinued by the Sponsor on 14 October 2019 due to slow enrollment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Treprostinil0/41 (0%)11/41 (26.8%)37/41 (90.2%)
Placebo1/43 (2.3%)8/43 (18.6%)38/43 (88.4%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventOral TreprostinilPlacebo
Fluid overloadMetabolism and nutrition disorders2/411/43
Cardiac failure acuteCardiac disorders1/412/43
Acute kidney injuryRenal and urinary disorders1/410/43
Atrial fibrillationCardiac disorders1/411/43
Bronchitis viralInfections and infestations1/410/43
DyspnoeaRespiratory, thoracic and mediastinal disorders1/411/43
FibromyalgiaMusculoskeletal and connective tissue disorders1/410/43
Gastritis erosiveGastrointestinal disorders1/410/43
HyperkalaemiaMetabolism and nutrition disorders1/410/43
HypokalaemiaMetabolism and nutrition disorders1/410/43
Most frequent other events
Showing 10 of 36
Most frequent other events
EventOral TreprostinilPlacebo
HeadacheNervous system disorders22/4112/43
DiarrhoeaGastrointestinal disorders19/4116/43
NauseaGastrointestinal disorders13/416/43
FatigueGeneral disorders8/4110/43
DyspnoeaRespiratory, thoracic and mediastinal disorders7/419/43
DizzinessNervous system disorders5/419/43
Pain in extremityMusculoskeletal and connective tissue disorders7/413/43
Upper respiratory tract infectionInfections and infestations3/417/43
Oedema peripheralGeneral disorders5/416/43
ArthralgiaMusculoskeletal and connective tissue disorders5/414/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)Oral TreprostinilPlaceboTotal
Median74.0 (53 to 85)74.0 (46 to 82)74.0 (46 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Oral TreprostinilPlaceboTotal
Female273158
Male141226
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral TreprostinilPlaceboTotal
Hispanic or Latino202
Not Hispanic or Latino394382
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral TreprostinilPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American178
White403676
More than one race000
Unknown or Not Reported000
Etiology of HFpEF
Etiology of HFpEF(Participants)Oral TreprostinilPlaceboTotal
Hypertension212849
Coronary artery disease8311
Obesity011
Diabetes202
Other101121
08

Study locations

82 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Banner University Medical Center Phoenix
    Phoenix, Arizona 85006, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • VA Healthcare System of Greater Los Angeles
    Los Angeles, California 90073, United States
  • University of California Los Angeles Pulmonary Division
    Los Angeles, California 90095, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90211, United States
  • University of California - Davis Medical Center
    Sacramento, California 95817, United States
  • Santa Barbara Cottage Hospital
    Santa Barbara, California 93105, United States
  • Aurora Denver Cardiology Associates
    Aurora, Colorado 80012, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • South Denver Cardiology
    Littleton, Colorado 80120, United States
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Medical Faculty Associates, George Washington University
    Washington, District of Columbia 20037, United States
  • Bay Area Cardiology Associates
    Brandon, Florida 33511, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • St. Vincent's Lung, Sleep, and Critical Care Specialists
    Jacksonville, Florida 33204, United States
  • Central Florida Pulmonary Group, P.A.
    Orlando, Florida 32803, United States
  • Florida Hospital
    Orlando, Florida 32806, United States
  • University of South Florida; Tampa General Hospital
    Tampa, Florida 33606, United States
  • Cleveland Clinic of Florida
    Weston, Florida 33331, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Piedmont Physicians Georgia Lung
    Austell, Georgia 30309, United States
  • WellStar Medical Group
    Marietta, Georgia 30060, United States
  • University of Illinois at Chicago Hospital
    Chicago, Illinois 60612, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • OSF HealthCare
    Peoria, Illinois 61614, United States
  • Indiana University Health Methodist Research Institute, INC
    Indianapolis, Indiana 46202, United States
  • Community Physician Network, Heart and Vascular Care
    Indianapolis, Indiana 46250, United States
  • Saint Vincent Hospital and Health Services
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 55242, United States
  • Iowa Heart Center
    West Des Moines, Iowa 50266, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky 40202, United States
  • University of Louisville Physicians Outpatient Center
    Louisville, Kentucky 40202, United States
  • Chest Medicine Associates
    South Portland, Maine 04106, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • St. Elizabeth's Medical Center
    Brighton, Massachusetts 02135, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Spectrum Health Medical Group
    Grand Rapids, Michigan 49503, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • St. Luke's Hospital
    Chesterfield, Missouri 63017, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Barnabas Health Lung Center
    Newark, New Jersey 07112, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Pulmonary Health Physicians, PC
    Syracuse, New York 13066, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28803, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Pinehurst Medical Clinic
    Pinehurst, North Carolina 28374, United States
  • The Lindner Research Center The Christ Hospital Health Network
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • University of Toledo Medical Center
    Toledo, Ohio 43614, United States
  • The Oregon Clinic
    Portland, Oregon 97225, United States
  • Lancaster General Hospital
    Lancaster, Pennsylvania 17601, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • AnMed Health Pulmonary and Sleep Medicine
    Anderson, South Carolina 29621, United States
  • VitaLink Research - Anderson
    Anderson, South Carolina 29621, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Stern Cardiovascular Foundation
    Germantown, Tennessee 38138, United States
  • Summit Medical Group
    Knoxville, Tennessee 37909, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Texas Tech University Health Sciences Center
    Lubbock, Texas 79905, United States
  • Intermountain Medical Center
    Murray, Utah 84157-7000, United States
  • Inova Heart and Vascular Institute
    Falls Church, Virginia 22042, United States
  • Sentara Cardiovascular Research Institute
    Norfolk, Virginia 23507, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Carilion Clinic
    Roanoke, Virginia 24014, United States
  • Providence Medical Research Center
    Spokane, Washington 99204, United States
  • West Virginia University Hospital
    Morgantown, West Virginia 26506, United States
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Dec 2019, 27 months.

Results were first posted in Oct 2020, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2017
First posted
Jan 31, 2017
StartActual
Aug 15, 2017
Primary completionActual
Dec 3, 2019
CompletionActual
Dec 3, 2019
Results first posted
Oct 22, 2020
Last update
Nov 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03037580
Responsible party
Sponsor
First posted
Jan 31, 2017
Start date
Aug 15, 2017
Primary completion
Dec 3, 2019
Completion
Dec 3, 2019
Results posted
Oct 22, 2020
Last update
Nov 10, 2020

Study contacts

Mardi Gomberg-Maitland, MD
principal investigator · George Washington University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion